rxstat › Classes › Antipsychotics
Antipsychotics: shortage status in Canada
11 of the 19 antipsychotics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.
Periciazine (Neuleptil) Widespread shortage 2 of 4 reported products affected
Trifluoperazine Widespread shortage 5 of 5 reported products affected
Haloperidol Partial shortage 6 of 16 reported products affected · est. return Nov 30, 2026
Lithium Carbonate (Carbolith) Partial shortage 4 of 11 reported products affected
Loxapine (Xylac) Partial shortage 4 of 10 reported products affected
Lurasidone (Latuda) Partial shortage 1 of 19 reported products affected · est. return Dec 24, 2026
Methotrimeprazine (Methoprazine) Partial shortage 1 of 5 reported products affected · est. return Nov 13, 2026
Prochlorperazine Partial shortage 1 of 3 reported products affected · est. return Nov 20, 2026
Quetiapine (Seroquel) Partial shortage 44 of 117 reported products affected · est. return Feb 26, 2027
Risperidone Partial shortage 16 of 81 reported products affected · est. return Jun 1, 2027
Ziprasidone (Zeldox) Partial shortage 3 of 8 reported products affected · est. return Jan 5, 2027
Olanzapine (Zyprexa) Shortage anticipated 0 of 106 reported products affected
Paliperidone (Invega) Shortage anticipated 0 of 4 reported products affected
Aripiprazole (Abilify) No current shortage
Chlorpromazine No current shortage
Clozapine No current shortage
Fluphenazine No current shortage
Perphenazine No current shortage
Pimozide (Orap) Discontinued 0 of 2 reported products affected
Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.